Research collaboration launched to focus on repurposing existing anti-viral therapies to treat COVID-19
On Feb. 4, 2022, a new ﾣ1.6m collaborative project was launched to rapidly identify new treatments for COVID-19….
-
-
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
-
T2 Biosystems T2SARS-CoV-2 panel detects Omicron subvariants
On Feb. 3, 2022, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected Omicron COVID-19 subvariants BA.1, BA.2, and…
-
New Zealand’s Medsafe granted provisional approval for Novavax’ COVID-19 vaccine
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
-
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
-
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
-
Cocrystal Pharma selected two lead antiviral drug candidates for COVID-19 oral drug program
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for further…
-
Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19
On Jan. 27, 2022, NIAID announced that a clinical trial found that the combination of remdesivir plus a…
-
International research team found nine new coronavirus species
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
-
Report published in PNAS detailed spread and evolution of SARS-CoV-2 in white-tailed deer across the U.S.
On Jan. 25. 2022, a report published in PNAS provided strong evidence of extensive SARS-CoV-2 infection of white-tailed…
-
Cepheid received Health Canada license for Xpert Xpress CoV-2/Flu/RSV plus
On Jan. 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
-
USDA announced study with zoos and aquariums to identify animal species susceptible to SARS-CoV-2
On Jan. 25, 2022, the U.S. Department of Agricultureﾒs National Veterinary Services Laboratories announced a study with zoos…
-
University of Missouri researchers identified mutations of Delta, Delta Plus variants
On Jan. 25, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
-
Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
-
Biotechnology | COVID-19 | NIH | Therapeutics
‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
-
Australia Therapeutic Goods Administration granted provisional registration for Novavax COVID-19 vaccine
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
-
U.S. FDA authorizd InteliSwabﾙ COVID-19 rapid tests for at-home testing for delta variant detection
On Jan. 13, 2022, OraSure Technologies that its InteliSwabﾮ COVID-19 rapid tests detected the Omicron variant as effectively…
-
South Korea Ministry of Food and Drug Safety approved Novavax COVID-19 vaccine
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
-
DoD awarded contract to Revival Health to purchase COVID-19 Antigen OTC kits in support of POTUS’ 500 million free at-home COVID-19 rests
On Jan. 7, 2022, the Department of Defense, in coordination with the U.S. Department of Health and Human…
-
Hologic added Aptima SARS-CoV-2 assay to its Global Access Initiative in resource-limited countries
On Jan 5, 2022, Hologic the addition of the Aptimaﾮ SARS-CoV-2 assay to its Global Access Initiative, a…
-
Revelar Biotherapeutics and Twist Bioscience announced RBT-0813 neutralized SARS-CoV-2 Omicron and Delta variants
On Jan 5, 2022, Revelar Biotherapeutics and Twist Bioscience announced that RBT-0813 binded to and neutralized the Omicron…
-
Pfizer provided U.S. Government with additional 10 million treatment courses of oral therapy to help combat COVID-19
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
-
Tonix Pharma announced exclusive collaboration with Kansas State University to develop LNP-Free mRNA vaccines
On Jan. 4, 2022, Tonix Pharmaceuticals announced an exclusive option agreement and research collaboration with Kansas State University…
-
U.S. DoD awarded $136.7 million to MilliporeSigma for domestic production capacity of COVID-19 point-of-care tests parts
On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S….
-
Biotechnology | COVID-19 | Disease | Genomics
PacBio’s HiFiViral Surveillance Kit Performance not impacted by Omicron mutations
On Dec. 28, 2021, Pacific Biosciences announced that its new HiFiViral SARS-CoV-2 solution had successfully sequenced and captured…
-
Development of WRAI’s pan-coronavirus vaccine showed promise
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
-
Sorrento announced COVISTIX COVID-19 virus rapid antigen detection test detected the Omicron variant
On Dec. 27, 2021, Sorrento Therapeutics announced that initial testing of COVISTIX on recombinant N proteins demonstrated its…
-
Roche COVID-19 at-home test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
On Dec. 24, 2021, Roche announced that the U.S. Food and Drug Administration had granted Emergency Use Authorization…
-
Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanﾒs Ministry of Health, Labor and Welfare had…
-
Biotechnology | COVID-19 | FDA | Medicine | Pharmaceutical | Therapeutics
Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
